VivoSeq
Other

Moderate to Severe Glabellar Frown Lines

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Moderate to Severe Glabellar Frown Lines is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Unknown status1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
Unknown status·AATGC Co., Ltd.·Phase 3·NCT05623410·300 enrolled
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
Completed·AATGC Co., Ltd.·Phase 1/2·NCT04281095·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)